Of particular note, patients with NAFLD show significantly higher fasting plasma glucagon levels (either normoglycemic or T2D) than normoglycemic and T2D control subjects without NAFLD (113). The gene discussed is GCG; the disease is metabolic dysfunction-associated steatotic liver disease.